Exhibit 99.1 Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the third quarter ended September 30, 2024, and updated it ...

MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at ...

MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peerreviewed journal Clinical Ophthalmology. Key study findings reported in the study manuscript inc ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $21.4 million, reflecting an 11% sequential growth but a 9% decrease compared to Q2 2023 [22][24] - Surgical Glaucoma revenue was $20.2 million, down 5% year-over-year but up 11% sequentially [22][24] - Dry Eye revenue was $1.1 million, down 46% compared to Q2 2023, primarily due to fewer new accounts and reduced sales infrastructure [22][24] - Gross margin for Q2 2024 was 86%, flat year-over-year, with Surgical Glaucoma gross margin at 88% and Dry Eye gross margin at 46% [23][24] Business Segment Data and Key Metrics Changes - Surgical Glaucoma segment showed sequential growth of 11% in revenue, with increased utilization and accounts ordering products [8][22] - Dry Eye segment faced a significant decline in revenue due to strategic shifts and fewer new accounts [22][23] Market Data and Key Metrics Changes - The company is focused on increasing surgeon utilization and reengaging accounts that decreased orders during the LCD uncertainty period [11][12] - The proposed Medicare payment rules for 2025 could enhance the value proposition for OMNI technology, potentially increasing facility payment rates by approximately $600 or 29% [10][26] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven without raising additional equity capital and is focused on long-term growth opportunities [22][24] - The strategy for the Dry Eye segment is shifting towards achieving fair reimbursement, with a price increase for TearCare expected to impact cash pay volume in the short term [20][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in regaining commercial momentum and achieving double-digit growth in the Surgical Glaucoma segment in the second half of 2024 [26][31] - The company is optimistic about the long-term growth potential in both Surgical Glaucoma and Dry Eye markets, with expectations for strong revenue growth in 2025 [21][27] Other Important Information - The company ended Q2 2024 with $118.2 million in cash and cash equivalents and $35 million in debt, reflecting disciplined cash usage [25] - The company is undergoing a patent infringement case against Alcon, with pending rulings that could impact future financials [25] Q&A Session Summary Question: Potential deceleration in Surgical Glaucoma growth - Management acknowledged the impact of previous LCD proposals on growth but expects to regain double-digit growth in the second half of 2024 due to favorable proposed LCDs [30][31] Question: 2025 growth expectations and cash flow breakeven revenue - Management did not provide specific 2025 guidance but expressed confidence in achieving significant growth and improving cash flow efficiency [32][34] Question: Expectations for cash burn in H2 2024 - Management anticipates continued improvements in cash burn while investing in key business areas [37][38] Question: TearCare claims and adoption rates - Management noted that it is still early in the process of getting claims paid for TearCare, with low volume but positive early responses [42][43] Question: OMNI usage mix and standalone reimbursement - Management estimated that about 85% of procedures are done in combination with cataract surgery, with ongoing efforts to develop the standalone market [46][48] Question: Update on conversations with commercial payers for TearCare - Management reported positive early conversations with payers, driven by strong clinical evidence and economic benefits of TearCare [54][56]

Financial Performance - Sight Sciences, Inc. reported a quarterly loss of $0.25 per share, better than the Zacks Consensus Estimate of a loss of $0.31, and improved from a loss of $0.30 per share a year ago, representing an earnings surprise of 19.35% [1] - The company posted revenues of $21.37 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.25%, but down from $23.47 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Sight Sciences shares have increased approximately 50.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $21.09 million, and for the current fiscal year, it is -$1.13 on revenues of $84.15 million [7] Industry Outlook - The Medical - Instruments industry, to which Sight Sciences belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Sight Sciences' stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

© 2024 Sight Sciences. All rights reserved. The Sustainability Report includes: Governance Practices: Disclosure of Sight Sciences' governance framework, ethical standards, and commitment to transparency and accountability, including reporting on information security breaches. For additional information and highlights, please see the full Sustainability Report, which can be found here. All Environmental, Social, and Governance ("ESG") practices are overseen by the Company's Nominating and Corporate Governan ...

MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company's sustainability activities, performance, and results from the last three years. Environmental Initiatives: Details of Sight Sciences' effort ...

Core Insights - Sight Sciences, Inc. announced the twelve-month results from the SAHARA trial, demonstrating the effectiveness of TearCare in treating dry eye disease (DED) compared to Restasis [1][3][11] Study Results - Patients previously treated with Restasis showed clinically meaningful improvements in DED symptoms after switching to TearCare, with benefits lasting for six months post-treatment [2][6] - Phase 2 of the SAHARA trial confirmed that TearCare is effective regardless of prior Restasis treatment, indicating its potential as both a primary and secondary treatment option for DED [3][4] - The trial included 345 subjects in Phase 1 and 163 patients crossed over to TearCare in Phase 2, with significant improvements in tear break-up time (TBUT) and other dry eye measures [4][5] Statistical Findings - TBUT improved by 1.1 seconds at three months and 0.6 seconds at twelve months after switching to TearCare, both statistically significant (p<.001) [8] - Other measures, including meibomian gland secretion score (MGSS) and ocular surface disease index (OSDI), also showed significant improvements post-treatment [8][10] - The study reported that mean values for TBUT, MGSS, and other ocular signs improved significantly compared to baseline measurements [10][11] Future Directions - The SAHARA trial will continue into Phase 3, which aims to provide long-term data on the durability and effectiveness of TearCare over a two-year period [11]

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

Core Insights - Sight Sciences, Inc. announced new findings from the ROMEO study, indicating that the OMNI Surgical System is effective in treating advanced glaucoma patients, challenging previous beliefs about treatment efficacy in severe cases [1][2][3] Group 1: Study Findings - The analysis showed that ab interno canaloplasty combined with trabeculotomy using OMNI effectively lowered intraocular pressure (IOP) and reduced medication usage across all glaucoma severity stages [2][3] - Significant reductions in IOP and IOP-reducing medications were observed, with 70% of eyes experiencing IOP reduction at Month 12, and 92% achieving levels of 18 mmHg or less [7] - The mean IOP at Month 12 ranged between 14 mmHg and 16 mmHg across severity groups, indicating consistent treatment outcomes [7] - Medication reductions were noted in 50% to 69% of patients, with the majority showing a reduction of at least one medication [7] - Regression analysis indicated no significant relationship between Month 12 IOP and visual field loss, suggesting treatment effectiveness is independent of disease severity [7] Group 2: Company Overview - Sight Sciences is focused on developing innovative eyecare technologies aimed at transforming patient care and improving lives, particularly through minimally invasive procedures [1][8] - The OMNI Surgical System is FDA-cleared for reducing IOP in adult patients with primary open-angle glaucoma, and it is CE Marked for additional procedures [8] - The company also offers the TearCare System for treating evaporative dry eye disease and the SION Surgical Instrument for ophthalmic surgeries [8]